}}</ref><ref name=Siller>{{cite journal | journal = Australas J Dermatol | añu = 2009 | volume = 50 | issue = 1 | pages = 16–22 | titletítulu = PEP005 (ingenol mebutate) xel, a novel agent for the treatment of actinic keratosis: results of a randomized, double-blind, vehicle-controlled, multicentre, phase IIa study | author = Siller G, Gebauer K, Welburn P, Katsamas J, Ogbourne SM | pmid = 19178487 | doi = 10.1111/j.1440-0960.2008.00497.x}}</ref><ref>Lebwohl, M, et al. "Ingenol Mebutate Xel for Actinic Keratosis." ''N Engl J Med 366'';11, March 15, 2012.</ref><ref>{{cita web|url=http://finance.yahoo.com/news/fda-approves-picato-ingenol-mebutate-130200825.html|títulu=FDA Approves Picato® (ingenol mebutate) Xel, the First and Only Topical Actinic Keratosis (AK) Therapy With 2 or 3 Consecutive Days of Once-Daily Dosing|fecha=25 de xineru de 2012|obra=eMedicine|editorial=Yahoo! Finance}}</ref>
